These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3118589)

  • 41. Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.
    Hartmann D; Korn A; Komjati M; Heinz G; Haefelfinger P; Defoin R; Waldhäusl WK
    Br J Clin Pharmacol; 1990 Aug; 30(2):245-52. PubMed ID: 2119677
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lack of influence of body mass index on efficacy and tolerance of acemetacin in short-term treatment of musculoskeletal diseases.
    Dejaco C; Duftner C; Schirmer M
    Rheumatol Int; 2007 Feb; 27(4):351-5. PubMed ID: 16957886
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A double-blind trial comparing indomethacin sustained release capsules (Indocid-R) with indomethacin capsules in patients with rheumatoid arthritis.
    Rhymer AR; Hart CB; Daurio C
    Rheumatol Rehabil; 1982 May; 21(2):101-6. PubMed ID: 7043710
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patients' preference in indomethacin trials: an overview.
    Gøtzsche PC
    Lancet; 1989 Jan; 1(8629):88-91. PubMed ID: 2562891
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A clinical study on the effect of K-708 (acemetacin)--a double blind comparative study with ibuprofen in upper respiratory tract inflammation with fever (author's transl)].
    Kitamoto O; Kobayashi H; Kaji M; Kashiwagi S; Hayashida K; Shingu T; Hara K; Izumikawa K; Fukui M; Ikebe A; Yamaguchi K; Suzuyama Y; Horiuchi N; Komori M; Fujimori I; Hayakawa Y; Katayama T; Kohno M; Sekita K; Tanaka T
    Kansenshogaku Zasshi; 1981 Sep; 55(9):614-29. PubMed ID: 6798146
    [No Abstract]   [Full Text] [Related]  

  • 46. Some studies of feprazone.
    Haslock I; Burkinshaw L; Berry DJ; Donovan B; Wright V
    Rheumatol Rehabil; 1976 May; 15(2):81-6. PubMed ID: 132695
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pellagra-like changes following glibenclamide treatment in a patient with diabetes mellitus and vitiligo].
    Berova N; Lazarova A
    Dermatol Monatsschr; 1988; 174(1):50-1. PubMed ID: 2965658
    [No Abstract]   [Full Text] [Related]  

  • 48. Adverse effect on diabetes control of concomitant glibenclamide and tolbutamide.
    Katsumata K; Katsumata Y
    Lancet; 1991 Mar; 337(8741):614. PubMed ID: 1671966
    [No Abstract]   [Full Text] [Related]  

  • 49. Benoxaprofen: a clinical trial with an unusual design.
    Huskisson EC; Scott J; Dieppe P
    Rheumatol Rehabil; 1978 Nov; 17(4):254-8. PubMed ID: 366721
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glibenclamide causing thrombocytopenia and bleeding tendency: case reports and a review of the literature.
    Israeli A; Matzner Y; Or R; Raz I
    Klin Wochenschr; 1988 Mar; 66(5):223-4. PubMed ID: 3129615
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Method for the determination of acemetacin, a non-steroidal anti-inflammatory drug, in plasma by high-performance liquid chromatography.
    Notarianni LJ; Collins AJ
    J Chromatogr; 1987 Jan; 413():305-8. PubMed ID: 3558683
    [No Abstract]   [Full Text] [Related]  

  • 52. [Polymorphism of acemetacin, a new antiinflammatory drug (author's transl)].
    Yoneda M; Ohkawa Y; Watanabe Y; Ogawa M; Nagai H
    Yakugaku Zasshi; 1981 Oct; 101(10):939-44. PubMed ID: 6978393
    [No Abstract]   [Full Text] [Related]  

  • 53. [Cholestasis from glibenclamide].
    Marriott Díaz E; Miranda Baiochi R; Hernández-Guío C
    Rev Esp Enferm Dig; 1990 Jun; 77(6):456-7. PubMed ID: 2121195
    [No Abstract]   [Full Text] [Related]  

  • 54. Can Nonsteroidal Anti-Inflammatory Drugs Lead to First-Time Heart Failure in Patients with Diabetes Mellitus Type-2: Is There a Link?
    Tabassum S; Naeem A; Khawaja UA; Nashwan AJ
    Pharmacology; 2023; 108(5):492-494. PubMed ID: 37499643
    [No Abstract]   [Full Text] [Related]  

  • 55. [Interactions of oral anti-diabetic agents and non-steroid anti-rheumatic agents].
    Knüsel O
    Z Rheumatol; 1984; 43(2):75-82. PubMed ID: 6730730
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Interactions of non-steroidal antirheumatic drugs with oral antidiabetic agents: acemetacin--glibenclamide].
    Haupt E; Hoppe FK; Rechziegler H; Zündorf P
    Z Rheumatol; 1987; 46(4):170-3. PubMed ID: 3118589
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A double-blind, randomized, controlled parallel group study evaluating the efficacy and safety of acemetacin for the management of osteoarthritis.
    Chou CT; Tsai YY
    Int J Clin Pharmacol Res; 2002; 22(1):1-6. PubMed ID: 12395912
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The influence of acemetacin and indometacin on gastrointestinal blood loss in normal volunteers and rheumatic patients (author's transl)].
    Uthgenannt H; Mohing W; Köhler G; Schmidt F; Havemann R
    Arzneimittelforschung; 1980; 30(8A):1424-7. PubMed ID: 6968220
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized study of glibenclamide versus traditional Chinese treatment in type 2 diabetic patients. Chinese-French Scientific Committee for the Study of Diabetes.
    Vray M; Attali JR
    Diabete Metab; 1995 Dec; 21(6):433-9. PubMed ID: 8593925
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clinical profile of acemetacin].
    Rechziegler H; Thebud-Lassak R
    Med Klin (Munich); 1990 May; 85(5):340-6, 352. PubMed ID: 2192250
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.